EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Refractory Acute Myeloid Leukemia following Extended Peptide Receptor Radionuclide Therapy for Well-Differentiated GEP-NETs: A Case Report

Alda Aleksi, Sarah Hussain, Michael Asamoah-Boaheng

Case Reports in Oncology · 2026-09-05 · 19 (1) · 1671-1687

DOI: 10.1159/cro/abzag046 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE is an established treatment for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. However, the incidence and risk profile of therapy-related myeloid neoplasms following extended 177Lu-DOTATATE exposure particularly beyond the standard four-cycle regimen remain poorly defined. Case Presentation: We report a 49-year-old woman with a well-differentiated jejunal neuroendocrine tumor with hepatic and peritoneal metastases who underwent bowel resection and limited hepatic metastatectomy, followed by long-acting somatostatin analog therapy and subsequent enrollment in a provincial PRRT clinical trial. She received 12 cycles of 177Lu-DOTATATE over 5 years (4 induction, 8 maintenance), without prior cytotoxic chemotherapy or external-beam radiotherapy, achieving durable biochemical and radiologic disease stability with minimal early toxicity. In late 2023, she developed progressive pancytopenia. Bone marrow examination in September 2024 revealed high-risk therapy-related acute myeloid leukemia (AML) characterized by inv(3)(q21q26.2), monosomy 7, complex cytogenetics, and a KRAS mutation. Her leukemia was refractory to intensive induction and subsequent lower-intensity therapy. She died on January 13, 2025, from progressive refractory AML with multiorgan dysfunction and central nervous system involvement. Conclusion: This case highlights a rare but life-threatening late hematologic toxicity associated with extended 177Lu-DOTATATE exposure and underscores the importance of long-term hematologic surveillance and critical evaluation of PRRT maintenance strategies beyond the standard four-cycle protocol.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →